Quantinno Capital Management LP Acquires 739 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Quantinno Capital Management LP raised its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 8.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,013 shares of the company’s stock after purchasing an additional 739 shares during the quarter. Quantinno Capital Management LP’s holdings in Prestige Consumer Healthcare were worth $704,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Avior Wealth Management LLC lifted its holdings in shares of Prestige Consumer Healthcare by 1,570.7% in the 4th quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock worth $668,000 after acquiring an additional 8,042 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 5.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock worth $49,667,000 after acquiring an additional 33,844 shares during the last quarter. Norges Bank bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter worth about $40,009,000. Barclays PLC lifted its holdings in shares of Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after acquiring an additional 71,730 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Prestige Consumer Healthcare by 1,073.3% in the 4th quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company’s stock worth $15,923,000 after acquiring an additional 186,524 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Up 1.1%

PBH stock opened at $85.98 on Friday. The company has a market capitalization of $4.25 billion, a PE ratio of 20.14, a P/E/G ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a 12 month low of $62.35 and a 12 month high of $90.04. The firm’s 50-day moving average is $83.52 and its 200 day moving average is $82.25. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. The company had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.02 EPS. On average, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PBH shares. Royal Bank of Canada upgraded shares of Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. Canaccord Genuity Group raised their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Oppenheimer raised their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, May 17th. Finally, DA Davidson raised their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.33.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.